DNA

Metagenomi Announces New Appointment to its Board of Directors

EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing…

11 months ago

Access Healthcare Announces Growth Investment from New Mountain Capital

Investment supports Access Healthcare's plans to accelerate transformation of revenue management for healthcare organizations NEW YORK and DALLAS, Jan. 14,…

11 months ago

Illumina and NVIDIA collaborate to decode biology and propel precision health

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan.…

11 months ago

Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology…

11 months ago

Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ --…

11 months ago

Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Cmbio®, a global leader in multi-omics science and digital biology, is pleased to…

12 months ago

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic…

12 months ago

Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot’s Operations

SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a…

12 months ago

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1…

12 months ago

NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology,…

12 months ago